Ascendis Pharma A/S $ASND Shares Bought by American Century Companies Inc.

American Century Companies Inc. lifted its position in Ascendis Pharma A/S (NASDAQ:ASND) by 14.9% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 530,809 shares of the biotechnology company’s stock after buying an additional 68,638 shares during the period. American Century Companies Inc. owned approximately 0.87% of Ascendis Pharma A/S worth $91,619,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Allianz Asset Management GmbH lifted its holdings in Ascendis Pharma A/S by 144.7% in the 2nd quarter. Allianz Asset Management GmbH now owns 9,300 shares of the biotechnology company’s stock valued at $1,605,000 after acquiring an additional 5,500 shares during the last quarter. Hantz Financial Services Inc. grew its stake in shares of Ascendis Pharma A/S by 291.1% in the 2nd quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 262 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Ascendis Pharma A/S by 10.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 585,581 shares of the biotechnology company’s stock worth $91,269,000 after purchasing an additional 55,164 shares in the last quarter. Vident Advisory LLC bought a new stake in shares of Ascendis Pharma A/S in the 1st quarter worth approximately $273,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Ascendis Pharma A/S during the second quarter valued at approximately $682,000.

Ascendis Pharma A/S Stock Down 1.1%

ASND opened at $206.65 on Wednesday. The firm has a market capitalization of $12.75 billion, a P/E ratio of -40.05 and a beta of 0.44. The stock has a fifty day moving average of $203.66 and a 200-day moving average of $187.18. Ascendis Pharma A/S has a 12-month low of $118.03 and a 12-month high of $223.18.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The company had revenue of $290.24 million during the quarter, compared to analysts’ expectations of $246.91 million. On average, analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on ASND shares. Bank of America lifted their price target on shares of Ascendis Pharma A/S from $227.00 to $230.00 and gave the stock a “buy” rating in a research report on Tuesday, September 2nd. Wolfe Research assumed coverage on Ascendis Pharma A/S in a research note on Tuesday, November 18th. They set a “peer perform” rating and a $255.00 price objective for the company. Cowen restated a “buy” rating on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Royal Bank Of Canada upped their target price on Ascendis Pharma A/S from $210.00 to $230.00 and gave the company an “outperform” rating in a report on Friday, August 8th. Finally, Wedbush reiterated an “outperform” rating and issued a $220.00 price target on shares of Ascendis Pharma A/S in a research report on Tuesday, November 18th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $256.60.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.